SUPPORTIVE evidence for the
adoption of a two-dose human
papillomavirus (HPV) vaccination
schedule continues to build,
moving Australia closer to the new
protocol, according to an article in
the Medical Journal of Australia.
Although unlikely to be in place
for 2017 school year, Associate
Professor Julia Brotherton, medical
director of the National HPV
Vaccination Program Register, said
around 65% of countries that have
HPV on their vaccine schedule
shifting from three- to two-dose
regimens.
Brotherton’s comments came as
research in the Journal of Infectious
Diseases demonstrated that a two dose
regimen of the HPV 16/18
AS04-adjuvanted vaccine in girls
aged 9–14 years was non-inferior
to a three-dose regimen in women
aged 15–25 years.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Aug 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.